BioCentury | Oct 3, 2017
Distillery Therapeutics

Other

...College of Medicine, Houston, Texas email: hzoghbi@bcm.edu Chris Lieu Baylor College of Medicine Dual Therapeutics LLC Lixte Biotechnology Holdings Inc. PEP-Therapy S.A.S. Methyl...
BioCentury | Jun 15, 2017
Tools & Techniques

Breaking the barrier

...therapeutic peptide (gold ribbon) to a cell-penetrating motif (blue tail) , a strategy pursued by Pep-Therapy S.A.S....
...is targeting β-catenin for metastatic colorectal cancer. In addition to Xigen, the category also includes Pep-Therapy S.A.S....
...Co. Inc. (NYSE:MRK), Kenilworth, N.J. NoNO Inc., Toronto, Ontario Orum Therapeutics Inc., Daejeon, South Korea PEP-Therapy S.A.S....
BioCentury | Jan 18, 2017
Translation in Brief

Keep a cool head

...favor of more potent antitumor agents. Lixte Biotechnology Holdings Inc. (OTCQB:LIXT), Dual Therapeutics LLC and PEP-Therapy S.A.S....
BioCentury | Nov 2, 2015
Emerging Company Profile

Targeted disruption

...and colleagues at the Institut National de la Santé et de la Recherche Médicale (INSERM). PEP-Therapy's...
...due to a difference in proteins that associate with the complex in cancer cells, but PEP-Therapy...
...activators to restore levels of PPP2CA to normal in cancers where the protein is down-regulated. PEP-Therapy...
BioCentury | Jul 27, 2015
Company News

CleveXel Pharma, PEP-Therapy deal

...The companies partnered to co-develop a peptide from PEP-Therapy to treat cancer through clinical proof of...
...preclinical testing. The companies said clinical testing is slated to begin at year end 2016. PEP-Therapy...
...financial details, and CleveXel did not respond to inquiries. CleveXel Pharma S.A.S. , Maisons-Alfort, France PEP-Therapy S.A.S....
BioCentury | May 4, 2015
Financial News

PEP-Therapy completes venture financing

PEP-Therapy S.A.S. , Evry, France Business: Cancer Date completed: 2015-04-27 Type: Venture financing Raised: EUR1.3 million ($1.4 million) Investors: Seventure Partners; private investor WIR Staff cancer...
Items per page:
1 - 6 of 6
BioCentury | Oct 3, 2017
Distillery Therapeutics

Other

...College of Medicine, Houston, Texas email: hzoghbi@bcm.edu Chris Lieu Baylor College of Medicine Dual Therapeutics LLC Lixte Biotechnology Holdings Inc. PEP-Therapy S.A.S. Methyl...
BioCentury | Jun 15, 2017
Tools & Techniques

Breaking the barrier

...therapeutic peptide (gold ribbon) to a cell-penetrating motif (blue tail) , a strategy pursued by Pep-Therapy S.A.S....
...is targeting β-catenin for metastatic colorectal cancer. In addition to Xigen, the category also includes Pep-Therapy S.A.S....
...Co. Inc. (NYSE:MRK), Kenilworth, N.J. NoNO Inc., Toronto, Ontario Orum Therapeutics Inc., Daejeon, South Korea PEP-Therapy S.A.S....
BioCentury | Jan 18, 2017
Translation in Brief

Keep a cool head

...favor of more potent antitumor agents. Lixte Biotechnology Holdings Inc. (OTCQB:LIXT), Dual Therapeutics LLC and PEP-Therapy S.A.S....
BioCentury | Nov 2, 2015
Emerging Company Profile

Targeted disruption

...and colleagues at the Institut National de la Santé et de la Recherche Médicale (INSERM). PEP-Therapy's...
...due to a difference in proteins that associate with the complex in cancer cells, but PEP-Therapy...
...activators to restore levels of PPP2CA to normal in cancers where the protein is down-regulated. PEP-Therapy...
BioCentury | Jul 27, 2015
Company News

CleveXel Pharma, PEP-Therapy deal

...The companies partnered to co-develop a peptide from PEP-Therapy to treat cancer through clinical proof of...
...preclinical testing. The companies said clinical testing is slated to begin at year end 2016. PEP-Therapy...
...financial details, and CleveXel did not respond to inquiries. CleveXel Pharma S.A.S. , Maisons-Alfort, France PEP-Therapy S.A.S....
BioCentury | May 4, 2015
Financial News

PEP-Therapy completes venture financing

PEP-Therapy S.A.S. , Evry, France Business: Cancer Date completed: 2015-04-27 Type: Venture financing Raised: EUR1.3 million ($1.4 million) Investors: Seventure Partners; private investor WIR Staff cancer...
Items per page:
1 - 6 of 6